Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel (Testosterone 50–100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up.

Next Previous
X
Search
Trial Profile

Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel (Testosterone 50–100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Therapeutic Use
  • Acronyms PADAM
  • Sponsors Bayer

    • Most Recent Events

    • 07 Jul 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Actual number of patients (363) and trial identifier (91297) added as reported by CT.gov
    • 07 Oct 2008 Actual end date (Oct 2007) added as reported by CT.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top